SILENCE THERAPEUTICS

Silence Therapeutics placed 14,907,407 American Depositary Shares (each ADS = 3 ordinary shares) at $13.50 per ADS, raising gross proceeds of approximately $201.3 million. The syndicate banks fully exercised the overallotment option and sold an additional 1,944,444 ADS. Jefferies, Morgan Stanley, Cantor and William Blair led the transaction, which was based on a registration statement that became effective on May 27, 2026. » Más en de.investing.com

Silence Therapeutics’ share slipped in premarket trading after about 12.96 million American Depositary Shares were placed at $13.50; gross proceeds are reported at roughly $175 million before fees. The syndicate banks have a 30‑day option for up to 1.94 million additional ADS, which could mean further dilution. Positive drivers included phase‑2 topline data from the SANRECO study and Morgan Stanley’s confirmation of an “Overweight” rating with an increased $32 price target. The narrower net result in Q2 year‑on‑year was accompanied by weaker revenue, so the short‑term pressure on the share price is mainly due to dilution caused by the offering discount. » Más en de.investing.com

Silence Therapeutics has set the price for a public offering of 12,962,963 American Depositary Shares (ADS) at $13.50 each, implying gross proceeds of about $175 million. The syndicate banks were granted a 30-day option to purchase up to 1,944,444 additional ADS. Completion of the offering is expected on Thursday, subject to customary conditions; Jefferies, Morgan Stanley, Cantor and William Blair are acting as joint book‑running managers. » Más en de.investing.com